Invex Therapeutics (ASX:IXC) Total Assets : A$6.28 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Invex Therapeutics Total Assets?

Invex Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was A$6.28 Mil.

During the past 12 months, Invex Therapeutics's average Total Assets Growth Rate was -71.60% per year. During the past 3 years, the average Total Assets Growth Rate was 65.40% per year.

During the past 5 years, Invex Therapeutics's highest 3-Year average Total Assets Growth Rate was 65.40%. The lowest was 41.90%. And the median was 53.65%.

Total Assets is connected with ROA %. Invex Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 was -29.06%. Total Assets is also linked to Revenue through Asset Turnover. Invex Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

Invex Therapeutics Total Assets Historical Data

The historical data trend for Invex Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invex Therapeutics Total Assets Chart

Invex Therapeutics Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Jun24

Total Assets

26.42

32.74

29.49

22.80

6.12

Invex Therapeutics Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Total Assets	Get a 7-Day Free Trial					29.49	25.90	22.80	6.28	6.12

Invex Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Invex Therapeutics's Total Assets for the fiscal year that ended in Jun. 2024 is calculated as

Total Assets	=	Total Equity (A: Jun. 2024 )	+	Total Liabilities (A: Jun. 2024 )
	=	5.688	+	0.432
	=	6.12

Invex Therapeutics's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	5.296	+	0.985
	=	6.28

Invex Therapeutics (ASX:IXC) Total Assets Explanation

Total Assets is connected with ROA %.

Invex Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	-4.226	/	( (22.804	+	6.28)	/ 2 )
	=	-4.226	/	14.542
	=	-29.06 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Invex Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	0	/	( (22.804	+	6.28)	/ 2 )
=	0	/	14.542
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Invex Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Invex Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Invex Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invex Therapeutics Ltd (ASX:IXC) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

38 Rowland Street, Level 1, Subiaco, WA, AUS, 6008

Website

https://www.invextherapeutics.com

Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.